Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Zoetis Inc is a drug manufacturers-specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars. Zoetis employs 12,100 staff and has a trailing 12-month revenue of around $8 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $151.35 |
|---|---|
| 52-week range | $147.77 - $247.98 |
| 50-day moving average | $165.49 |
| 200-day moving average | $183.19 |
| Wall St. target price | $228.73 |
| PE ratio | 33.615 |
| Dividend yield | $1.15 (0.87%) |
| Earnings per share (TTM) | $4.41 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $151.35 from 2022-10-03
| 1 week (2022-09-27) | 1.31% |
|---|---|
| 1 month (2022-09-02) | -3.59% |
| 3 months (2022-07-01) | -13.12% |
| 6 months (2022-04-01) | -20.80% |
| 1 year (2021-10-04) | -21.86% |
|---|---|
| 2 years (2020-10-02) | -7.46% |
| 3 years (2019-10-04) | 19.13% |
| 5 years (2017-10-04) | 138.08% |
Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Zoetis shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5553. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.
The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $8 billion |
|---|---|
| Operating margin TTM | 35.58% |
| Gross profit TTM | $5.5 billion |
| Return on assets TTM | 12.77% |
| Return on equity TTM | 4680.85% |
| Profit margin | 26.14% |
| Book value | $9.77 |
| Market capitalisation | $69.4 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 01/01/2019) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.72/100
Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13/100
Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.87/100
Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.
Zoetis Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.6 |
|---|---|
| Total ESG percentile | 49.38 |
| Environmental score | 2.72 |
| Environmental score percentile | 1 |
| Social score | 13 |
| Social score percentile | 1 |
| Governance score | 8.87 |
| Governance score percentile | 1 |
| Level of controversy | 1 |
Dividend payout ratio: 25.68% of net profits
Recently Zoetis has paid out, on average, around 25.68% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.87% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.87% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $1.15 per share.
While Zoetis's payout ratio might seem fairly standard, it's worth remembering that Zoetis may be investing much of the rest of its net profits in future growth.
Zoetis's most recent dividend payout was on 1 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 20 July 2022 (the "ex-dividend date").
Over the last 12 months, Zoetis's shares have ranged in value from as little as $147.77 up to $247.9802. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.7627. This would suggest that Zoetis's shares are less volatile than average (for this exchange).
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
